Financing - May 8, 2019
Swedish life sciences: Options to finance operations broadening
A survey among SwedenBIO’s members shows that the growing Swedish life science sector has during the last ten years extended its possibilities to finance its operations. The results, published today in a report entitled Bridging the Gap, also show that the industry enjoyed a record level of refunding activities in 2018, securing new share capital […]
Financing - April 10, 2019
Biovica completes a directed new share issue of SEK 60 million
The company has resolved to carry out a directed new share issue of Class B Shares at a subscription price of SEK 10 per share. The directed new share issue was substantially over-subscribed with large interest from institutional investors in the Nordics and Europe. Through the directed new share issue and subject to the approval of […]
Financing - April 4, 2019
Gesynta Pharma secures EUR 6 million for development programs
The company has completed a financing round to provide funds for early clinical development of its lead candidate, GS-248. A consortium consisting of venture capital investor Industrifonden and a group of private life sciences investors provides financial and strategic support to Gesynta’s development programs and brings the company to its next pivotal milestone, to make […]
Financing - April 4, 2019
Gradientech raises USD 4.6 million
The Swedish biotechnology company Gradientech has closed a fully subscribed rights issue totalling USD 4.6 million (SEK 42.5 million). Existing owners, as well as new parties appointed by Erik Penser Bank AB, who acted as financial advisor, have subscribed. Bird & Bird Lawyers acted as legal advisors. The company’s largest rights issue “We have now […]
Financing - March 22, 2019
Zhejiang NHU invests €5.5 million in Danish biotech start-up
The Chinese fine chemical company Zhejiang NHU will invest €5.5 M in the biotech start-up CysBio to develop new and affordable biochemicals. CysBio is making cost-effective and novel biochemicals via sustainable fermentation processes. Through advanced synthetic biology and metabolic engineering approaches microorganisms are engineered to convert simple sugars into desired biochemical products. This makes it […]
Financing - March 22, 2019
Cantargia makes directed share issue of approximately SEK 106 million
The proceeds from the share issue enable expanded investments in the company’s main project, CAN04 (nidanilimab), with a new clinical study in the US and an expansion of the most promising patient sub group of the ongoing clinical CANFOUR study. The investors are a number of Nordic institutional investors; Alecta (approximately SEK 76.5 million), Handelsbanken […]
